SLC5A2 and diabetes mellitus: The DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial was designed to evaluate the efficacy and safety of the SGLT2 inhibitor dapagliflozin in patients with HFrEF, regardless of the presence or absence of diabetes [21–23].